Rare Disease

Enabling access and improving outcomes for patients with rare disease
Rare Disease

Rare Disease Consulting

Alkemi partners with stakeholders who seek to advance rare disease therapeutics, disease outcomes and patient access.

Rare Disease Expertise

Alkemi collaborates with life science companies, patient advocates, guideline groups, medical thought-leaders, and payers to develop the appropriate evidence and insights required to advance rare disease outcomes. Our publications include research on unmet needs in rare disease therapeutic areas, including oncology and immunology.

Recent Publications

Presentation
ACAAI 2023
Cribbs, K., Lahue, B.J.
Nov 2023
Presentation
ISPOR EU 2023
Lahue, B.J., Cribbs, K.
Nov 2023
Presentation
ISPOR EU 2023
Baisley, W., Lahue, B.J.
Nov 2023

Our Rare Disease Specialization

Strategic Evidence Generation

Why is it important to be strategic when it comes to evidence generation? Designing and executing studies is resource intensive. Additionally, patient lives and well-being are at stake, so time is at a premium.

Alkemi partners with clients to create a strategy that is efficient, targeted and informed with decision-maker insights. Our evidence generation strategies often encompass rare disease, real world evidence, health economics and outcomes research to achieve market access. Our goal – like yours – is to ensure novel treatments reach the patients in greatest need. 

Our team of experienced researchers and market access consultants specialize in the following:

Evidence Generation Insights

Health Economics and Outcomes Research

Analytical Support

Publication Strategy

Payer Communications

HEOR Partner